Symbols

INSM

Insmed·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INSM

Insmed Incorporated

A biopharmaceutical company focused on developing and commercializing innovative therapies for rare and serious diseases

Industry

Pharmaceutical

Established Date

11/29/1999

Listing Date

06/01/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,664

Fiscal Year Ends

12-31

Website

www.insmed.com

Security Type

Common stock

Office address

700 US Highway 202/206, Bridgewater, New Jersey 08807

Business

Introduction

Insmed Incorporated was incorporated in the Commonwealth of Virginia on November 29, 1999, and its main administrative offices are located in Bridgewater, New Jersey. Insmed is a people-centred biopharmaceutical company dedicated to providing best-in-class, first-of-its-kind therapies to transform the lives of patients with serious diseases. Its commercial portfolio and clinical pipeline focus on three therapeutic areas: respiratory system, immunology and inflammation, and neurological and other rare.

Company Financials

EPS

INSM has released its 2025 Q4 earnings. EPS was reported at -1.54, versus the expected -1.17, missing expectations. The chart below visualizes how INSM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

INSM has released its 2025 Q4 earnings report, with revenue of 263.84M, reflecting a YoY change of 152.62%, and net profit of -328.49M, showing a YoY change of -39.46%. The Sankey diagram below clearly presents INSM's revenue sources and cost distribution.